

Dosing and Administration¹

Recommended dose

The dose of Vascepa[®] is 4 grams/day taken as:

Two 1 gram capsules, twice daily with food



AM



PM

Administration

Patients should be advised to swallow Vascepa[®] capsules whole. The patient should not break open, crush, dissolve, or chew Vascepa[®].

Missed dose

If the patient misses:

One dose of Vascepa[®]

They should take the dose as soon as they remember

One day of Vascepa[®]

They should not double the dose when they take their next dose


Vascepa[®] (icosapent ethyl) is indicated to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to:

- ▶ established cardiovascular disease, or
- ▶ diabetes, and at least one other cardiovascular risk factor¹



Co-pay card available to help get your patients started on Vascepa® —for more information, call 1-877-790-1991.

Please consult the Vascepa® Product Monograph at <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp> for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use which have not been discussed in this piece.

The Product Monograph is also available by calling HLS Therapeutics Inc. at 1-833-266-3423.



The image shows a patient assistance card for Vascepa. On the left, the text reads "Pr Vascepa® (icosapent ethyl)". To the right is a photograph of a white, oval-shaped tablet with "VASCEPA" embossed on it. Below the product name, there is a QR code and a table of information:

PATIENT ASSISTANCE			
	Carrier 32	Group 999	Client ID BRAND ABCDE 123MB 

At the bottom right of the card is the "sti" logo.

To learn more, visit www.vascepa.ca

Reference:

1. HLS Therapeutics Inc. Vascepa® Product Monograph. 2019.

Vascepa® is a registered trademark of the Amarin group of companies.

© Copyright 2020 HLS Therapeutics Inc.
HLS Therapeutics Inc.
Etobicoke, Ontario
M9W 6L2
VAS 20200242 E COM



NEW
Pr **Vascepa**®
(icosapent ethyl)